Information Provided By:
Fly News Breaks for May 31, 2016
ICPT
May 31, 2016 | 09:24 EDT
Morgan Stanley analyst Andrew Berens said Intercept Ocaliva approval on Friday was expected but believes the thesis will shift to commercial execution in PBC, which will likely pressure shares given the clinical data section does note the lack of data in these patients and viability. Berens rates Intercept an Underweight with an $80 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.